The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for Regeneron 色界吧s鈥� investigational antibody cocktail, REGEN-COV (casirivimab and imdevimab) to prevent Covid-19.
REGEN-COV is a combination of two monoclonal antibodies, casirivimab and imdevimab, that can hinder SARS-CoV-2 infectivity.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The updated authorisation allows the use of REGEN-COV for post-exposure prophylaxis in individuals at increased risk for progression to severe Covid-19, who are not completely vaccinated or may not have a proper response to vaccines.
In addition, the therapy can be used in people who were exposed to a person infected with SARS-CoV-2, or who are at increased risk of exposure to an infected person in an institutional setting, including nursing homes or prisons.
Regeneron noted that the antibody cocktail can be given every month to people who need repeated doses for ongoing exposure.
Subcutaneous injection or intravenous infusion of REGEN-COV is authorised for post-exposure prophylaxis.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn November last year,聽the antibody cocktail obtained FDA EUA聽for the treatment of mild to moderate Covid-19 patients who are at high risk for progressing to severe Covid-19 and/or hospitalisation.
The latest indication is apart from the EUA granted for the use of聽a reduced dose – 1,200mg – of REGEN-COV in June this year.
Regeneron 色界吧s president and chief scientific officer George Yancopoulos said: 鈥淭oday鈥檚 FDA authorisation enables certain people at high risk of聽developing severe Covid-19 infection聽to access REGEN-COV if they have been聽exposed聽to the virus 鈥� the first time an antibody treatment has been authorised for this purpose.
鈥淲ith this authorisation, the FDA specifically highlights the needs of immunocompromised people, including those taking immunosuppressive medicines, who may not mount an adequate response to vaccination, who are exposed to a person with Covid-19 or are in an institutional setting and are at high risk of exposure because of infection occurring in the same setting.鈥�
The expanded EUA for post-exposure prophylaxis is based on results from Phase III clinical trial聽which demonstrated REGEN-COV鈥檚 ability聽to lower the risk of symptomatic Covid-19 infections by 81% in聽close contacts of SARS-CoV-2-infected people.
Furthermore, the company noted that REGEN-COV is not indicated for pre-exposure prophylaxis for Covid-19 prevention and is not an alternative for vaccination.
